S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
3 Stocks Set to Lead the Nasdaq Bull Market
How This Rare Metal Is Going To Solve A $173 TRILLION World Problem… And Could Benefit Investors (Ad)
Companies facing 1st tax on stock buybacks in Biden bill
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
Copper Exploration Heating Up (Ad)
Stocks end higher on Wall Street; economic worries hit oil
Is Ford About To Crush Workhorse Group? 
3 Blowout Earnings Reports That Could Mark Turning Points
Copper More Critical than Lithium? (Ad)
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
3 Stocks Set to Lead the Nasdaq Bull Market
How This Rare Metal Is Going To Solve A $173 TRILLION World Problem… And Could Benefit Investors (Ad)
Companies facing 1st tax on stock buybacks in Biden bill
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
Copper Exploration Heating Up (Ad)
Stocks end higher on Wall Street; economic worries hit oil
Is Ford About To Crush Workhorse Group? 
3 Blowout Earnings Reports That Could Mark Turning Points
Copper More Critical than Lithium? (Ad)
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
3 Stocks Set to Lead the Nasdaq Bull Market
How This Rare Metal Is Going To Solve A $173 TRILLION World Problem… And Could Benefit Investors (Ad)
Companies facing 1st tax on stock buybacks in Biden bill
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
Copper Exploration Heating Up (Ad)
Stocks end higher on Wall Street; economic worries hit oil
Is Ford About To Crush Workhorse Group? 
3 Blowout Earnings Reports That Could Mark Turning Points
Copper More Critical than Lithium? (Ad)
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
3 Stocks Set to Lead the Nasdaq Bull Market
How This Rare Metal Is Going To Solve A $173 TRILLION World Problem… And Could Benefit Investors (Ad)
Companies facing 1st tax on stock buybacks in Biden bill
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
Copper Exploration Heating Up (Ad)
Stocks end higher on Wall Street; economic worries hit oil
Is Ford About To Crush Workhorse Group? 
3 Blowout Earnings Reports That Could Mark Turning Points
Copper More Critical than Lithium? (Ad)
NASDAQ:CLSD

Clearside Biomedical - CLSD Stock Forecast, Price & News

$1.54
-0.05 (-3.14%)
(As of 08/15/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.51
$1.60
50-Day Range
$1.30
$1.83
52-Week Range
$1.26
$7.73
Volume
94,532 shs
Average Volume
132,141 shs
Market Capitalization
$92.63 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00

Clearside Biomedical MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
419.5% Upside
$8.00 Price Target
Short Interest
Healthy
0.97% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.73mentions of Clearside Biomedical in the last 14 days
Based on 15 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.36) to ($0.22) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.46 out of 5 stars

Medical Sector

218th out of 1,125 stocks

Pharmaceutical Preparations Industry

98th out of 554 stocks

CLSD stock logo

About Clearside Biomedical (NASDAQ:CLSD) Stock

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

Clearside Biomedical Stock Down 3.1 %

Shares of NASDAQ:CLSD opened at $1.54 on Tuesday. The company has a 50-day moving average price of $1.56 and a 200 day moving average price of $1.71. Clearside Biomedical has a 12 month low of $1.26 and a 12 month high of $7.73.

Clearside Biomedical (NASDAQ:CLSD - Get Rating) last issued its quarterly earnings data on Tuesday, August 9th. The company reported ($0.13) EPS for the quarter, hitting analysts' consensus estimates of ($0.13). Clearside Biomedical had a negative net margin of 5.54% and a negative return on equity of 5.60%. During the same period in the prior year, the business earned ($0.11) earnings per share. Research analysts expect that Clearside Biomedical will post -0.36 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently commented on the company. StockNews.com upgraded Clearside Biomedical from a "hold" rating to a "buy" rating in a research report on Wednesday, August 10th. HC Wainwright cut their price objective on shares of Clearside Biomedical from $10.00 to $5.00 and set a "buy" rating on the stock in a report on Wednesday, August 10th. Finally, TheStreet lowered shares of Clearside Biomedical from a "c" rating to a "d+" rating in a research note on Wednesday, May 11th. Four analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $8.00.

Receive CLSD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Clearside Biomedical and its competitors with MarketBeat's FREE daily newsletter.

CLSD Stock News Headlines

Clearside Biomedical Q1 2022 Earnings Preview
See More Headlines
Receive CLSD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Clearside Biomedical and its competitors with MarketBeat's FREE daily newsletter.

CLSD Company Calendar

Last Earnings
8/09/2022
Today
8/16/2022
Next Earnings (Estimated)
11/09/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CLSD
Employees
34
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$8.00
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+419.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$380,000.00
Pretax Margin
0.28%

Debt

Sales & Book Value

Annual Sales
$29.58 million
Book Value
$0.64 per share

Miscellaneous

Free Float
52,932,000
Market Cap
$92.63 million
Optionable
Optionable
Beta
1.90














CLSD Stock - Frequently Asked Questions

Should I buy or sell Clearside Biomedical stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Clearside Biomedical in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CLSD shares.
View CLSD analyst ratings
or view top-rated stocks.

What is Clearside Biomedical's stock price forecast for 2022?

3 equities research analysts have issued 1 year price objectives for Clearside Biomedical's shares. Their CLSD share price forecasts range from $5.00 to $10.00. On average, they anticipate the company's stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 419.5% from the stock's current price.
View analysts price targets for CLSD
or view top-rated stocks among Wall Street analysts.

How have CLSD shares performed in 2022?

Clearside Biomedical's stock was trading at $2.75 on January 1st, 2022. Since then, CLSD shares have decreased by 44.0% and is now trading at $1.54.
View the best growth stocks for 2022 here
.

When is Clearside Biomedical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our CLSD earnings forecast
.

How were Clearside Biomedical's earnings last quarter?

Clearside Biomedical, Inc. (NASDAQ:CLSD) issued its earnings results on Tuesday, August, 9th. The company reported ($0.13) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.13). Clearside Biomedical had a negative trailing twelve-month return on equity of 5.60% and a negative net margin of 5.54%. During the same period last year, the firm earned ($0.11) earnings per share.

What other stocks do shareholders of Clearside Biomedical own?
When did Clearside Biomedical IPO?

(CLSD) raised $50 million in an IPO on Thursday, June 2nd 2016. The company issued 7,200,000 shares at a price of $7.00 per share. Cowen and Company and Stifel served as the underwriters for the IPO and Needham & Company, Wedbush PacGrow was co-manager.

What is Clearside Biomedical's stock symbol?

Clearside Biomedical trades on the NASDAQ under the ticker symbol "CLSD."

Who are Clearside Biomedical's major shareholders?

Clearside Biomedical's stock is owned by a number of retail and institutional investors. Top institutional investors include Carmignac Gestion (3.97%), Renaissance Technologies LLC (1.34%), Assenagon Asset Management S.A. (1.26%), Millennium Management LLC (0.51%), Northern Trust Corp (0.15%) and Franklin Resources Inc. (0.13%). Insiders that own company stock include Bradford T Whitmore, Bradford T Whitmore, Charles A Deignan, Clay Thorp, George M Lasezkay, George M Lasezkay, Nancy J Hutson, Richard T Burke, Thomas Ciulla and William D Humphries.
View institutional ownership trends
.

How do I buy shares of Clearside Biomedical?

Shares of CLSD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Clearside Biomedical's stock price today?

One share of CLSD stock can currently be purchased for approximately $1.54.

How much money does Clearside Biomedical make?

Clearside Biomedical (NASDAQ:CLSD) has a market capitalization of $92.63 million and generates $29.58 million in revenue each year. The company earns $380,000.00 in net income (profit) each year or ($0.03) on an earnings per share basis.

How can I contact Clearside Biomedical?

Clearside Biomedical's mailing address is 900 NORTH POINT PARKWAY SUITE 200, ALPHARETTA GA, 30005. The official website for the company is www.clearsidebio.com. The company can be reached via phone at (678) 270-3631, via email at charlie.deignan@clearsidebio.com, or via fax at 678-270-4033.

This page (NASDAQ:CLSD) was last updated on 8/16/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.